Cargando…

Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats

OBJECTIVE: Osteoarthritis (OA) is driven by low-grade inflammation, and controlling local inflammation may offer symptomatic relief. Here, we developed an indoleamine 2,3-dioxygenase and galectin-3 fusion protein (IDO-Gal3), where IDO increases the production of local anti-inflammatory metabolites a...

Descripción completa

Detalles Bibliográficos
Autores principales: Partain, Brittany D., Bracho-Sanchez, Evelyn, Farhadi, Shaheen A., Yarmola, Elena G., Keselowsky, Benjamin G., Hudalla, Gregory A., Allen, Kyle D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506271/
https://www.ncbi.nlm.nih.gov/pubmed/37723593
http://dx.doi.org/10.1186/s13075-023-03153-0
_version_ 1785107087331688448
author Partain, Brittany D.
Bracho-Sanchez, Evelyn
Farhadi, Shaheen A.
Yarmola, Elena G.
Keselowsky, Benjamin G.
Hudalla, Gregory A.
Allen, Kyle D.
author_facet Partain, Brittany D.
Bracho-Sanchez, Evelyn
Farhadi, Shaheen A.
Yarmola, Elena G.
Keselowsky, Benjamin G.
Hudalla, Gregory A.
Allen, Kyle D.
author_sort Partain, Brittany D.
collection PubMed
description OBJECTIVE: Osteoarthritis (OA) is driven by low-grade inflammation, and controlling local inflammation may offer symptomatic relief. Here, we developed an indoleamine 2,3-dioxygenase and galectin-3 fusion protein (IDO-Gal3), where IDO increases the production of local anti-inflammatory metabolites and Gal3 binds carbohydrates to extend IDO’s joint residence time. In this study, we evaluated IDO-Gal3’s ability to alter OA-associated inflammation and pain-related behaviors in a rat model of established knee OA. METHODS: Joint residence was first evaluated with an analog Gal3 fusion protein (NanoLuc™ and Gal3, NL-Gal3) that produces luminescence from furimazine. OA was induced in male Lewis rats via a medial collateral ligament and medial meniscus transection (MCLT + MMT). At 8 weeks, NL or NL-Gal3 were injected intra-articularly (n = 8 per group), and bioluminescence was tracked for 4 weeks. Next, IDO-Gal3s’s ability to modulate OA pain and inflammation was assessed. Again, OA was induced via MCLT + MMT in male Lewis rats, with IDO-Gal3 or saline injected into OA-affected knees at 8 weeks post-surgery (n = 7 per group). Gait and tactile sensitivity were then assessed weekly. At 12 weeks, intra-articular levels of IL6, CCL2, and CTXII were assessed. RESULTS: The Gal3 fusion increased joint residence in OA and contralateral knees (p < 0.0001). In OA-affected animals, both saline and IDO-Gal3 improved tactile sensitivity (p = 0.008), but IDO-Gal3 also increased walking velocities (p ≤ 0.033) and improved vertical ground reaction forces (p ≤ 0.04). Finally, IDO-Gal3 decreased intra-articular IL6 levels within the OA-affected joint (p = 0.0025). CONCLUSION: Intra-articular IDO-Gal3 delivery provided long-term modulation of joint inflammation and pain-related behaviors in rats with established OA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-023-03153-0.
format Online
Article
Text
id pubmed-10506271
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105062712023-09-19 Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats Partain, Brittany D. Bracho-Sanchez, Evelyn Farhadi, Shaheen A. Yarmola, Elena G. Keselowsky, Benjamin G. Hudalla, Gregory A. Allen, Kyle D. Arthritis Res Ther Research OBJECTIVE: Osteoarthritis (OA) is driven by low-grade inflammation, and controlling local inflammation may offer symptomatic relief. Here, we developed an indoleamine 2,3-dioxygenase and galectin-3 fusion protein (IDO-Gal3), where IDO increases the production of local anti-inflammatory metabolites and Gal3 binds carbohydrates to extend IDO’s joint residence time. In this study, we evaluated IDO-Gal3’s ability to alter OA-associated inflammation and pain-related behaviors in a rat model of established knee OA. METHODS: Joint residence was first evaluated with an analog Gal3 fusion protein (NanoLuc™ and Gal3, NL-Gal3) that produces luminescence from furimazine. OA was induced in male Lewis rats via a medial collateral ligament and medial meniscus transection (MCLT + MMT). At 8 weeks, NL or NL-Gal3 were injected intra-articularly (n = 8 per group), and bioluminescence was tracked for 4 weeks. Next, IDO-Gal3s’s ability to modulate OA pain and inflammation was assessed. Again, OA was induced via MCLT + MMT in male Lewis rats, with IDO-Gal3 or saline injected into OA-affected knees at 8 weeks post-surgery (n = 7 per group). Gait and tactile sensitivity were then assessed weekly. At 12 weeks, intra-articular levels of IL6, CCL2, and CTXII were assessed. RESULTS: The Gal3 fusion increased joint residence in OA and contralateral knees (p < 0.0001). In OA-affected animals, both saline and IDO-Gal3 improved tactile sensitivity (p = 0.008), but IDO-Gal3 also increased walking velocities (p ≤ 0.033) and improved vertical ground reaction forces (p ≤ 0.04). Finally, IDO-Gal3 decreased intra-articular IL6 levels within the OA-affected joint (p = 0.0025). CONCLUSION: Intra-articular IDO-Gal3 delivery provided long-term modulation of joint inflammation and pain-related behaviors in rats with established OA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-023-03153-0. BioMed Central 2023-09-18 2023 /pmc/articles/PMC10506271/ /pubmed/37723593 http://dx.doi.org/10.1186/s13075-023-03153-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Partain, Brittany D.
Bracho-Sanchez, Evelyn
Farhadi, Shaheen A.
Yarmola, Elena G.
Keselowsky, Benjamin G.
Hudalla, Gregory A.
Allen, Kyle D.
Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats
title Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats
title_full Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats
title_fullStr Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats
title_full_unstemmed Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats
title_short Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats
title_sort intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male lewis rats
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506271/
https://www.ncbi.nlm.nih.gov/pubmed/37723593
http://dx.doi.org/10.1186/s13075-023-03153-0
work_keys_str_mv AT partainbrittanyd intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats
AT brachosanchezevelyn intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats
AT farhadishaheena intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats
AT yarmolaelenag intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats
AT keselowskybenjaming intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats
AT hudallagregorya intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats
AT allenkyled intraarticulardeliveryofanindoleamine23dioxygenasegalectin3fusionproteinforosteoarthritistreatmentinmalelewisrats